What are the natural sources of kratom and which laboratory tests can be used to detect its use?

Kratom Origin and Laboratory Testing

Kratom comes from the leaves of Mitragyna speciosa, a tree native to Southeast Asia (particularly Thailand and surrounding regions), and standard urine drug screening panels do NOT detect kratom—you must specifically request specialized testing using liquid chromatography-tandem mass spectrometry (LC-MS/MS) or gas chromatography-mass spectrometry (GC-MS) to identify mitragynine and its metabolites.

Natural Source

Kratom is derived from Mitragyna speciosa, a plant in the Rubiaceae family 1. The psychoactive effects come from indole alkaloids present in the leaves, primarily mitragynine and 7-hydroxymitragynine 2. Commercial kratom products in the US market are predominantly whole-leaf material, not extracts, and maintain consistent alkaloid composition matching authentic M. speciosa leaf fingerprints 3.

Critical Testing Considerations

Why Standard Drug Screens Miss Kratom

Urine drug screening remains the gold standard for substance detection 4, but kratom alkaloids are NOT included in standard immunoassay panels. The typical drug screens that detect opiates (morphine, codeine) or synthetic opioids (oxycodone, hydrocodone) will not cross-react with kratom alkaloids 4. This is a critical pitfall—a negative standard urine drug screen does not rule out kratom use.

Specialized Testing Required

To detect kratom use, you must:

• Request specific kratom alkaloid testing from the laboratory
• Specify LC-MS/MS or GC-MS methodology 5, 6
• Target these compounds:
  • Mitragynine (primary alkaloid)
  • 7-hydroxymitragynine (active metabolite)
  • 5-desmethylmitragynine (metabolite)
  • 17-desmethyldihydromitragynine (metabolite)
  • Paynantheine, speciogynine, speciociliatine 7, 5

Detection Windows

• Urine: Mitragynine and metabolites can be detected, though specific timeframes are less established than traditional drugs of abuse
• Blood: Useful for recent use (2-12 hours) but rarely practical in primary care 4
• Hair: Can detect chronic use over 90 days but not useful for recent use (7-10 day lag) and is costly 4

Practical Testing Algorithm

1. Confirm laboratory capability: Before ordering, verify your laboratory offers kratom-specific testing using LC-MS/MS or GC-MS methodology 5, 6

2. Specify analytes: Request quantification of mitragynine (lower limit of quantification: 0.5-1.0 ng/mL in plasma, 1.00 ng/mL in urine) 5, 6

3. Interpret results cautiously:

   • Positive results confirm kratom exposure
   • Negative results on standard panels mean nothing—kratom requires specialized testing
   • False positives are unlikely with confirmatory MS methods 4

4. Consider clinical context: Average users consume 25-31 mg mitragynine per use, with daily intake ranging 50-135 mg 3. Accumulation occurs with daily use 6.

Important Caveats

• Verify what your laboratory actually tests: Many facilities do not routinely offer kratom panels—you must specifically request this 4
• Standard opioid immunoassays will NOT detect kratom despite its opioid-like effects 4
• Point-of-care tests for kratom are not widely available—laboratory-based confirmatory testing is necessary 5
• Newer formulations exist: Sublingual strips, buccal pouches, and vaping products containing kratom alkaloids are emerging, which bypass first-pass metabolism and have unknown pharmacokinetics 8

The most recent evidence shows whole-leaf kratom products in the US are generally unadulterated with prescription or illicit drugs 3, but specialized testing methodology is absolutely required for detection since kratom is invisible to standard drug screening approaches.